Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy

Curr Cardiol Rep. 2021 Jun 3;23(7):79. doi: 10.1007/s11886-021-01508-0.


Purpose of review: Pharmacological treatment options for hypertrophic cardiomyopathy (HCM) are currently limited and comprise non-disease specific therapies such as β-blockers, non-dihydropyridine calcium channel blockers, and disopyramide. These agents that offer a variable degree of symptomatic relief, often suboptimal, are often limited by side-effects and fail to address the key molecular abnormalities of the disease.

Recent findings: Mavacamten is a novel, first-in-class, allosteric inhibitor of cardiac myosin ATPase, which reduces actin-myosin cross-bridge formation, thereby reducing myocardial contractility and improving myocardial energetic consumption in experimental HCM models. Following a successful Phase 2 study, the recently published phase III, placebo-controlled, randomized EXPLORER-HCM trial demonstrated the efficacy and safety of mavacamten in reducing left ventricular outflow tract obstruction and ameliorating exercise capacity, New York Heart Association functional class and health status in patients with obstructive HCM. Mavacamten represents the first agent specifically developed for HCM successfully tested in a Phase III trial, to be registered soon for clinical use, representing a radical change of paradigm in the pharmacological treatment of HCM.

Trial registration: NCT04349072 NCT04219826.

Keywords: HCM; Hypertrophic cardiomyopathy; Mavacamten; Therapy.

Publication types

  • Review

MeSH terms

  • Benzylamines* / therapeutic use
  • Cardiac Myosins
  • Cardiomyopathy, Hypertrophic* / drug therapy
  • Clinical Trials, Phase III as Topic
  • Humans
  • Randomized Controlled Trials as Topic
  • Uracil* / analogs & derivatives


  • Benzylamines
  • MYK-461
  • Uracil
  • Cardiac Myosins

Associated data